GLOBAL CELL AND GENE THERAPY MARKET SIZE TO CROSS USD 14 BILLION BY 2025, GROWING AT A CAGR OF OVER 30% DURING THE FORECAST PERIOD

Cell and Gene Therapy Market Size, Share, & Trends Analysis Report by Product (Cell and Gene Therapy), Disease (Dermatology, Musculoskeletal, Oncology, Genetic Disorders, and Others), End-users (Hospitality, Cancer Care Centers, Wound Care Centers, Ambulatory Surgical Centers, and Others), and Geography (North America, APAC, Europe, Latin America, and Middle East & Africa), Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020–2025

GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Customize this Report

Most Exhaustive Report

266 Pages

53 Tables

137 Charts

5 Regions

18 Countries

38 Companies

4 Market Segment

CELL AND GENE THERAPY MARKET REPORT SCOPE

Report Attribute Details
MARKET SIZE (REVENUE) USD 14 BILLION (2025)
CAGR 30% (2020–2025)
Base Year 2019
Forecast Year 2020-2025
Market Segments Product (Cell and Gene Therapy), Disease (Dermatology, Musculoskeletal, Oncology, Genetic Disorders, and Others), End-users (Hospitality, Cancer Care Centers, Wound Care Centers, Ambulatory Surgical Centers, and Others)
Geographic Analysis North America, Europe, APAC, Latin America, and Middle East & Africa
Countries Covered US, Canada, UK, Germany, France, Spain, Italy, China, Japan, South Korea, Australia, India, Brazil, Mexico, Saudi Arabia, Turkey, UAE, and South Africa

INDUSTRY INSIGHTS

The global cell and gene therapy market size to cross USD 14 billion by 2025, growing at a CAGR of over 30% during the forecast period. The global cell and gene therapy market is one of the fastest-growing segments in the regenerative medicine market. The market is expected to grow at a faster pace during the forecast period. The demand can be attributed to the growing prevalence of several chronic diseases such as cancer, cartilage related problems, wounds, diabetic foot ulcer, genetic disorders, and other rare diseases across the globe. The prevalence of cancer and diabetes is increasing in the global population, which is influencing the growth of the market. There is a large unmet need in the treatment available, which is filled by cell and gene therapies. The market is growing due to the increased availability of funding from various public and private institutions. Besides, there is increased support from regulatory bodies for product approval. Several governments are creating awareness of cell and gene therapies in the population.

SNIPPETS

  • The gene therapy segment is expected to reach revenues of over $11 billion by 2025 due to the increased clinical efficacy of gene therapies to treat heart failures and other diseases.
  • The oncology segment is expected to reach $9.5 billion by 2025 on account of the high prevalence of cancer and other terminal illness.
  • The hospital segment is likely to observe an incremental growth of over $6 billion by 2025 due to the availability of advanced medical equipment and professionals.
  • North America is likely to register revenues of over $11.5 billion by 2025, driven by the high prevalence of diabetes and cancer and other terminal diseases along with the high elderly population.

GLOBAL CELL AND GENE THERAPY MARKET SEGMENTATION

This research report includes a detailed segmentation by

  • Products
  • Disease
  • End-users
  • Geography

INSIGHTS BY PRODUCT

The gene therapy segment is projected to grow at the highest CAGR during the forecast period. In 2019, the cell therapy segment accounted for a market share of over 53% in the global cell and gene therapy market. The segment is expected to grow at a steady rate during the forecast period due to the increase in the target population and the rise in the number of countries preferring cell therapies in their patients. Increased therapeutic benefits are attracting several countries to invest in this technology and conduct a high number of clinical trials. However, the lack of advanced infrastructure in developing countries is hindering the growth of the segment.

The gene therapy segment is expected to witness the fastest growth than cell therapy in the market. The high potential of treating diseases through gene therapies makes them more demanding than cell therapies. However, the lack of reimbursement is one of the significant challenges is limiting the usage of the cell and gene therapy segments.

INSIGHTS BY DISEASE

The genetic disorder segment is likely to register a staggering CAGR of close 35% during 2019­–2025. In 2019, the oncology segment accounted for a share of over 40% in the global cell and gene therapy market. Oncology has been one of the targets of intense research for the gene therapy procedures & approach. More than 60% of on-going gene therapy clinical trials are targeting cancer. The segment is expected to grow at a promising rate on account of the high prevalence of cancer diseases, especially in low and middle-come countries. The market is growing at a double-digit CAGR, which is expected to help the segment as many cell and gene therapy for cancer are commercially available.

The dermatology application segment in the cell and gene therapy includes wound care management among patients. Vendors are focusing on the development and commercialization of advanced wound care products for the treatment of chronic and acute wounds, thereby increasing the growth of the wound care market. The increased pervasiveness of diabetics is increasing acute and chronic wounds, including surgical wounds, pressure ulcers, diabetic foot ulcers, and other wounds.

The musculoskeletal segment is growing at a significant rate due to several factors, including an increase in the elderly population, growth in surgical volumes due to a high incidence of comorbidities and chronic inflammatory and degenerative conditions, such as osteoarthritis (OA) and tendonitis. At the same time, developed countries have started using cell therapy for the treatment of musculoskeletal disorders. Developing and underdeveloped countries are slowly adopting the usage of cell therapy.

INSIGHTS BY END-USERS

The hospital segment is projected to reach revenues of over $7 billion by 2025. In 2019, the hospital segment accounted for a share of over 40% in the global cell and gene therapy market. The market is growing due to the increasing incidence/prevalence of chronic diseases such as cancer, cardiovascular diseases, diabetes, chronic wounds due to diabetes foot, pressure ulcers, and other injuries. More patients would be admitted to hospital premises with an increased prevalence rate of these diseases.

In 2019, the wound care segment accounted for a share of over 16% in the global market. Most patients suffer from chronic wounds such as diabetic ulcers, pressure ulcers, and venous stasis ulcers, cause significant morbidities in millions of patients per year. Hence, individuals who have diabetes for a long period develop both peripheral vascular disease and peripheral neuropathy. The majority of healthcare professionals prefer to use gene therapy in humans for better healing. This is driving the demand for gene therapy process in wound management, especially in wound care centers. 

The cancer care centers end-user segment is expected to grow at a significant rate as the number of people who have cancer is increasing across the globe. One of the major advantages of specialized cancer care centers is the availability of experienced and specialized care. Several new therapies are introduced to patients through cancer care centers. There are many investigational studies conducted in cancer care centers for future new therapy launches. With advances in cancer care treatments, and the need for timely treatment delivery, the importance of cancer care centers is increasing each day.

INSIGHTS BY GEOGRAPHY

North America will continue to dominate the global cell and gene therapy market share. In 2019, North America accounted for a share of over 60% of the global cell and gene therapy market. There are more than 530 regenerative medicine companies, including cell and gene therapy manufacturing developers. The number of products approved in North America grew significantly in 2019, with developers filed for marketing authorization for 10+ regenerative medicines, many of which we expect to be approved in 2020. Within the next 1–2 years, the number of approved gene therapies is expected to double. The US and Canada are the major contributors to the cell and gene therapy market in North America. Regulatory bodies are supporting several investigational products, fast track approvals, RMAT designation for the faster approval of the product into the market. The alliance for regenerative medicine and Medicare and Medicaid is working together to bring the structured reimbursement channels for cell and gene therapies.

INSIGHTS BY VENDORS

The global cell and gene therapy market is highly dynamic and characterized by the presence of several global, regional, and local vendors offering a wide range of therapies. Dendreon, Gilead Sciences, Novartis, Organogenesis, Osiris Therapeutics, Vericel, Amgen, and Spark Therapeutics are the leading players in the market with significant shares. Vendors such as NuVasive, APAC Biotech, Nipro, Orthocell, bluebird bio, J-TEC, and Terumo are the other prominent players in the market with a presence, especially in the cell therapy market. Most leading players are focusing on implementing strategies such as product launches and approvals, marketing and promotional activities, acquisitions, increased R&D investments, and strengthening their distribution networks to enhance their share and presence in the market.

The global cell and gene therapy market report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:

Segmentation by Product

  • Cell Therapy
  • Gene Therapy

By Disease

  • Dermatology
  • Musculoskeletal
  • Oncology
  • Genetic Disorders
  • Others

By End-user

  • Hospitality
  • Cancer Care Centers
  • Wound Care Centers
  • Ambulatory Surgical Centers
  • Others

By Geography

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
  • APAC
    • China
    • Japan
    • South Korea
    • Australia
    • India
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • Saudi Arabia
    • Turkey
    • South Africa
    • UAE

Frequently Asked Questions

The global cell and gene therapy market size to cross $14 billion by 2025, growing at a cagr of over 30% during the 2020-2025
The following factors are likely to contribute to the growth of the cell and gene therapy market during the forecast period: Increase in Strategic Acquisition Activities Increased Funding for Cell & Gene Therapy Products Expanding Applications of Cell and Gene Therapies Increased in the Patient Pool
The hospital segment is likely to observe an incremental growth of over $6 billion by 2025 due to the availability of advanced medical equipment and professionals.
Some of the prominent vendors are Gilead Sciences, Spark Therapeutics, Novartis, Organogenesis, Amgen, Osiris Therapeutics, Dendreon, Vericel
The gene therapy segment is expected to witness the fastest growth than cell therapy in the market.
Read More

Select a license type that suits your business needs

Single User Licence
$3500.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5 User Licence
$4000.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
$5000.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Select a license type that suits your business needs

Best Value Tag
Coming Soon
  • Stay tuned with us.

YOU CAN GET A FREE SAMPLE OF THIS REPORT!

Fill out your details & get your free sample

Our Clients

Licence Types What are these?

Our Clients Speak

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date